en ENGLISH
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla reumatologów!
www.ereumatologia.pl
SCImago Journal & Country Rank


 
5/2020
vol. 58
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
Artykuł przeglądowy

Nephrotic syndrome in the course of type 1 diabetes mellitus and systemic lupus erythematosus with secondary antiphospholipid syndrome – diagnostic and therapeutic problems. A case-based review

Aleksandra Graca
1
,
Dorota Suszek
1
,
Radosław Jeleniewicz
1
,
Maria Majdan
1

1.
Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland
Reumatologia 2020; 58, 5: 331–334
Data publikacji online: 2020/10/20
Plik artykułu:
- Nephrotic syndrome.pdf  [0.07 MB]
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Nephrotic syndrome (NS) is a clinical condition characterized by daily loss of protein in the urine > 3.5 g/1.73 m²/day, hypoalbuminemia, hyperlipidemia, and the presence of edema. Most often, it is caused by primary glomerulonephritis (70%) [1]. In other patients, secondary glomerulopathies might be the cause of NS and are associated with [1]:

  • diabetes,

  • amyloidosis,

  • autoimmune diseases: systemic lupus erythematosus (SLE), systemic vasculitis,

  • infectious diseases: HIV, HBV, HCV, CMV, toxoplasmosis, parvovirus B19,

  • drug effects: gold salts, nonsteroidal anti-inflammatory drugs,

  • cancer,

  • renal vessel thrombosis: thrombotic microangiopathy, renal vein thrombosis.

Systemic lupus erythematosus is a chronic autoimmune disease that is associated with disturbances of acquired and innate immunity caused by various environmental factors and genetic predispositions. Lupus nephritis (LN) occurs in 35–75% of patients with SLE and manifests most commonly as glomerulonephritis [1, 2]. Proteinuria > 500 mg/day is the main symptom of LN. Also, NS may occur in the course of this disease. Lupus nephritis can also manifest as urinary changes such as granular casts, hematuria, and sterile leukocyturia, as well as acute kidney injury (AKI) or chronic kidney disease (CKD). In addition to clinical symptoms, kidney biopsy plays a key role in determining the diagnosis of LN. Based on the histopathological image, changes in kidneys can be classified into one of six classes (Table I) [3, 4].

Table I

Abbreviated International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis (2003, 2018) [3, 4]

Class IMinimal mesangial lupus nephritis
Class IIMesangial proliferative lupus nephritis
Class IIIFocal lupus nephritisa
Class IVDiffuse segmental (IV–S) or global (IV–G) lupus nephritisb
Class VMembranous lupus nephritisc
Class VIAdvanced sclerosing lupus nephritis
Indicate and grade (mild, moderate, severe) tubular atrophy, interstitial inflammation, and fibrosis, the severity of arteriosclerosis, or other vascular lesions

a Proportion of glomeruli with active and with sclerotic lesions.

b Proportion of glomeruli with fibrinoid necrosis and cellular crescents.

c Class V may occur in combination with class III or IV in which case both will be diagnosed.

Diabetic nephropathy is a functional and structural malfunctioning of the renal parenchyma due to chronic hyperglycemia. Diabetic nephropathy is a microangiopathic complication of diabetes and affects approximately 40% of diabetics. Microalbuminuria is an early symptom of diabetic nephropathy. 80% of patients with type 1 diabetes mellitus have overt proteinuria after 6–14 years of disease duration [5]. Diabetic kidney disease is currently the most common cause of end-stage renal disease (ESRD) [6]. Based on the histopathological image, diabetic nephropathy can be divided into four classes according to glomerular lesions (Table II) [7].

Table II

Glomerular classification of diabetic nephropathy [7]

Class IMild or nonspecific LM changes and EM-proven GBM thickening
Class IIA
Class IIB
Mild mesangial expansion
Severe mesangial expansion
Class IIINodular sclerosis (Kimmelstiel-Wilson lesion)
Class IVAdvanced diabetic glomerulosclerosis

[i] LM – light microscopy, EM – electron microscopy, GBM – glomerular basement membrane.

Material and methods

As a background for discussion a case of nephropathy which was initially treated as a complication of poorly controlled long-lasting type 1 diabetes (DMT1) is presented. In the described patient apart from kidney involvement, no other signs of systemic connective tissue disease were observed. Diagnosis for autoimmune diseases was carried out due to the progressive nature of nephropathy despite constant diabetes treatment and an episode of thrombosis. The results of serological tests supported the diagnosis of systemic disease: SLE/APS.

Such a coincidence of events prompted the search for other descriptions and answers to the described clinical problem. Therefore the literature was analyzed using key words: diabetes mellitus type 1 and lupus erythematosus, nephrotic syndrome, lupus nephritis.

Case report

A 28-year-old female patient with type 1 diabetes was diagnosed at the age of 13 (2004) and at the age 22 (2012) with onset of proteinuria (1.5 g/day) and eGFR 90 ml/min/1.73 m2; therefore DMT1 treatment was started using a personal insulin pump. In 2015 the patient was admitted to the Endocrinology Clinic due to weight gain and massive swelling of lower limbs. Laboratory tests revealed microcytic anemia (Hb 10.2 g/dl), leukopenia (3790/ml) with lymphopenia (1000/ml), hypoproteinemia with dysproteinemia (total protein – 5.7 g/dl, albumin – 3.18 g/dl), proteinuria (6.5 g/day), and hypercholesterolemia. Renal function parameters remained normal.

Additionally, immunological studies showed a reduced concentration of complement components C3 and C4, antinuclear antibodies (ANA) presented in titer 1 : 2560 with speckled staining pattern, whereas pANCA and cANCA antibodies were absent. In abdominal ultrasound, the kidneys had normal size and structure. The patient also had an episode of deep vein thrombosis in the left upper limb.

At the age of 26 (2016), the patient was admitted to the Department of Rheumatology and Systemic Connective Tissue Diseases. The patient denied skin, mucosal and joint symptoms. The immunoassay tests were repeated: ANA 1 : 2560, speckled staining pattern, SS-A (++), SS-B (+++), Rib P (++) present in the ENA panel, anti-dsDNA borderline, anti-cardiolipin antibodies present in the IgM class – aCL-IgM (160.4 MPL; norm < 20 MPL) and in the IgG class – aCL-IgG (38.1 GPL; norm < 20), lupus anticoagulant was absent, but Factor V Leiden mutation was present.

Based on the clinical image and the results of additional tests, SLE was diagnosed. Hydroxychloroquine at a dose of 200 mg/day was recommended for treatment. Three months later, the anti-phospholipid antibody assay was repeated. High-aCL-IgM and aCL-IgG were detected, and anti-beta2-glycoprotein I antibodies in the IgM and IgG class (anti-b2-GPI IgM and IgG) were present.

Antiphospholipid syndrome (APS) was diagnosed, and warfarin anticoagulation was initiated. Due to the unclear etiology of nephropathy (diabetic? in the course of SLE? APS?), the patient was qualified for kidney biopsy. The pathomorphological image corresponded to class IV lupus nephropathy. Glucocorticosteroid and cyclophosphamide (CYC) pulses were used in the Euro-Lupus regimen. After 3 γ CYC administration, partial remission of lupus nephropathy was achieved: total protein and albumin levels were normal, and proteinuria decreased (3.2 g/day). Mycophenolate mofetil (MMF) at a dose of up to 2 g/day was recommended for maintenance of remission, hydroxychloroquine, and anticoagulant therapy were continued. After achieving partial remission, the MMF dose was reduced to 1 g/day. Since then, the patient has remained without clinical symptoms of SLE: proteinuria < 1 g/day, and eGFR 78 ml/min/1.73 m2 (Fig. 1).

Fig. 1

The course of the disease in a patient with type 1 diabetes mellitus, systemic lupus erythematosus and antiphospholipid syndrome.

APS – antiphospholipid syndrome, CYC – cyclophosphamide, MMF – mycophenolate mofetil, SLE – systemic lupus erythematosus, NS – nephrotic syndrome.

/f/fulltexts/R/42144/RU-58-42144-g001_min.jpg

Discussion

Analysis of secondary nephrotic syndrome causes

Nephrotic syndrome is a common symptom of autoimmune diseases, especially SLE. The percentage of patients with lupus nephritis who have NS ranges from 30% to 70%. The presence of NS significantly worsens the prognosis in patients with SLE [8]. Epidemiological studies indicate the coexistence of various autoimmune diseases in one patient, most commonly Hashimoto’s disease, type 1 diabetes, albinism, or inflammatory joint diseases. The co-occurrence of one or more autoimmune diseases in one patient increases the risk of damage to organs they have involved, including kidney damage. About 30% of patients with SLE develop another autoimmune disease [9].

Patients with SLE are at an increased risk of developing diabetes. The comorbidity of SLE and type 1 diabetes is relatively rare. In the Kota et al. study [10], SLE was diagnosed in 3 of 260 patients with type 1 diabetes. Cortes et al. [11] analyzed a group of 485 patients with SLE. Type 1 and type 2 diabetes were diagnosed in 3 (0.61%) and 6 (0.82%) patients with SLE, respectively. Some patients with type 1 diabetes with insulin resistance associated with insulin receptor antibodies are more likely to develop SLE. In these patients, a variety of antibodies are found, including SLE marker antibodies against dsDNA [11]. Anti-insulin antibodies were found in 5 out of 27 (19%) patients with SLE [12, 13].

In the group of metabolic diseases, the most common cause of NS is diabetes, especially long-term and poorly controlled. Many studies show the co-morbidity of diabetes and kidney disease, which is not a consequence of diabetes but another associated disease [1417]. Both SLE and diabetes can lead to the development of NS and ESRD in a variety of mechanisms. The comorbidity of type 1 diabetes in patients with SLE significantly increases this risk [18, 19].

Renal involvement is associated both with primary and secondary APS. Antiphospholipid syndrome causes various pathophysiological effects concerning the kidneys [20, 21]. Antiphospholipid associated nephropathy (APSN), acute or chronic with nephritic or nephrotic syndrome, may be presented in kidney biopsy specimens as:

  • thrombotic microangiopathy (TMA),

  • fibrous intimal hyperplasia (FIH),

  • focal cortical atrophy (FCA).

However, the renal biopsy was a decisive test that allowed the diagnosis of lupus nephropathy and the exclusion of thrombotic changes in the course of APS. Only intensive immunosuppressive treatment with cyclophosphamide made it possible to achieve NS remission, which was maintained by introducing MMF in long-lasting treatment. Performing kidney biopsies in patients with nephropathy and diabetes should be considered particularly in patients with a short duration of diabetes, presence of hematuria, NS, or another systemic disease [2, 1417].

Conclusions

The comorbidity of SLE and diabetes and the symptoms of nephropathy can pose significant diagnostic difficulties and require a specific diagnostic approach. Differentiation of the underlying causes of kidney damage is crucial in undertaking the appropriate treatment. The nature of morphological changes in kidney biopsy may help in the diagnosis, classification of nephropathy, and further therapeutic decisions, which are different in diabetic nephropathy and lupus nephritis (diabetic kidney disease and lupus nephritis).

Notes

[5] Conflicts of interest The authors declare no conflict of interest.

References

1 

Kodner C , author. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016. 93:p. 479–485

2 

Reddy V, Isenberg D , authors; Adu D, Emery P, Madaio M , editors. Clinical presentation and assessment of disease activity in lupus nephritis. Rheumatology and the Kidney. 2012. p. 1–10

3 

Weening JJ, D’Agati VD, Schwartz MM, et al. , authors. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004. 15:p. 241–250. DOI: 10.1097/01.asn.0000108969.21691.5d

4 

Bajema IM, Wilhelmus S, Alpers ChE, et al. , authors. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018. 93:p. 789–796. DOI: 10.1016/j.kint.2017.11.023

5 

Bakris GL, Molitch M , authors. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014. 37:p. 867–875. DOI: 10.2337/dc13-1870

6 

Sanchez-Nińo MD, Benito-Martin A, Ortiz A , authors. New paradigms in cell death in human diabetic nephropathy. Kidney Int. 2010. 78:p. 737–744. DOI: 10.1038/ki.2010.270

7 

Tervaert TWC, Mooyaart AL, Amann K, et al. , authors. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010. 21:p. 556–563. DOI: 10.1681/ASN.2010010010

8 

Gomez Mendez LM, Cascino MD, Katsumoto TR, et al. , authors. Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus Sci Med. 2019. 6:p. e000308DOI: 10.1136/lupus-2018-000308

9 

Chambers SA, Charman SC, Rahman A, Isenberg D , authors. Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis. 2007. 66:p. 1173–1177. DOI: 10.1136/ard.2006.062984

10 

Kota SK, Meher LK, Jammula S, et al. , authors. Clinical profile of coexisting conditions in type 1 diabetes mellitus patients. Diabetes Metab Syndr. 2012. 6:p. 70–76. DOI: 10.1016/j.dsx.2012.08.006

11 

Cortes S, Chambers S, Jerónimo A, Isenberg D , authors. Diabetes mellitus complicating systemic lupus erythematosus – analysis of the UCL lupus cohort and review of the literature. Lupus. 2008. 17:p. 977–980. DOI: 10.1177/0961203308091539

12 

Heras P, Mantzioros M, Mendrinos D, et al. , authors. Autoantibodies in type 1 diabetes. Diabetes Res Clin Pract. 2010. 90:p. e40–42. DOI: 10.1016/j.diabres.2010.08.015

13 

Lidar M, Braf A, Givol N, et al. , authors. Anti-insulin antibodies and the natural autoimmune response in systemic lupus erythematosus. Lupus. 2001. 10:p. 81–86. DOI: 10.1191/096120301669081314

14 

Teng J, Dwyer KM, Hill P, et al. , authors. Spectrum of renal disease in diabetes. Nephrology (Carlton). 2014. 19:p. 528–536

15 

Grujicic M, Salapura A, Basta-Jovanovic G, et al. , authors. Non-diabetic kidney disease in patients with type 2 diabetes mellitus – 11-year experience from a single center. Med Arch. 2019. 73:p. 87–91. DOI: 10.5455/medarh.2019.73.87-91

16 

Zhuo L, Ren W, Li W, et al. , authors. Evaluation of renal biopsies in type 2 diabetic patients with kidney disease: a clinicopathological study of 216 cases. Int Urol Nephrol. 2013. 45:p. 173–179. DOI: 10.1007/s11255-012-0164-6

17 

Kveder R, Kajtna-Koselj, Rott T, Bern A , authors. Nephrotic syndrome in patients with diabetes mellitus is not always associated with diabetic nephropathy. Nephrol Dial Transplant. 2001. 16 Suppl 6:p. 86–87. DOI: 10.1093/ndt/16.suppl_6.86

18 

Jiang MY, Hwang JC, Feng IJ , authors. Impact of diabetes mellitus on the risk of end-stage renal disease in patients with systemic lupus erythematosus. Sci Rep. 2018. 8:p. 6008DOI: 10.1038/s41598-018-24529-2

19 

Munoz C, Isenberg DA , authors. Review of major endocrine abnormalities in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2019. 37:p. 791–796

20 

Bienaime F, Legendre Ch, Terzi F, et al. , authors. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017. 91:p. 34–44. DOI: 10.1016/j.kint.2016.06.026

21 

Majdan M , author. Kidney involvement in antiphospholipid syndrome – current diagnostic and management problems. Reumatologia. 2017. 55:p. 213–214. DOI: 10.5114/reum.2017.71626

Copyright: © 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
facebook linkedin twitter
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.